KKR Health Care Growth-backed Biosynth completed the acquisition of Pepceuticals.

KKR Health Care Growth-backed Biosynth, a supplier of critical materials to the life science industry, completed the acquisition of Pepceuticals, a UK producer of synthetic peptides with multi-kilogram GMP facilities and fill-finish capabilities designed to support customers from clinical trials to commercial supply. Financial terms were not disclosed. "We are very excited for Pepceuticals to be joining Biosynth. The Pepceuticals team has great expertise in optimizing the production of peptides and working at GMP and larger scales, making it a natural fit for Biosynth as we round out our peptide offering," Urs Spitz, Biosynth CEO and President.